The Relationship Between The Differential Expression Of FosB Protein In Laryngeal Cancer Tissues And Clinical Prognosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: the expression negative in laryngeal cancer tissue, the expression positive in laryngeal cancer tissue.
- Who it may be relevant to
- Registry conditions: Laryngeal Carcinoma. Basic parameters: 35 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Expression Of FosB Gene In Laryngeal Cancer Tissues And It's Clinical Prognosis Significance
Overview
To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods. If there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues
Detailed description
First,the investigators will collect 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in our institution in the past five years. Laryngeal cancer pathological tissues and adjacent tissues will be selected to make pathological sections. Use immunohistochemistry to confirm the differences in FosB protein between laryngeal cancer tissues and adjacent tissues, and clarify whether there are differences.
secondly,if there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. Review the clinical data of corresponding patients, including age, gender, smoking and alcohol history, clinical stages, pathological types and clinical prognosis, etc., and compare whether there are statistical differences.
Finally, clinical prognostic data of relevant patients were collected through outpatient follow-up, online and telephone follow-up, to determine whether there is a correlation between Fosb expression in laryngeal cancer tissue and clinical prognosis.
Interventions
- Other the expression negative in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods! - Other the expression positive in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
Primary outcome measures
- the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined. [Time frame: one month]
Secondary outcome measures (1)
- _Experimental result of western blot and PCR._Correlation analysis data between clinical information and experimental results.. [Time frame: three months]
Eligibility criteria
Inclusion criteria
- laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists;
- Primary tumor of Laryngeal ,and there was no distant metastasis;
- Standard treatment such as surgery and Preliminarily-diagnosed parients;
- full clinical and pathological data information and good follow-up;
- there was no previous fatal diseases such as complicated tumors.
Exclusion criteria
- Secondary cancer or cancer with distant metastasis;
- Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;
- Clinical and pathological data were missing and loss to follow-up;
- Patients who abandoned treatment or standard treatment procedures has not been completed;
- The past medical history of other lethal diseases such as complicated tumors.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
China · 1 center
- Cllinical Laboratory of Chuanbei Medical College — Nanchong
Publications
- Liu S, Luan J, Ding Y. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. Oncol Res. 2018 Jun 11;26(5):683-690. doi: 10.3727/096504017X14982585511252. Epub 2017 Jun 24. PMID 28653602
- Hung YP, Fletcher CD, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017 May;41(5):596-606. doi: 10.1097/PAS.0000000000000795. PMID 28009608
- Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003 Nov;3(11):859-68. doi: 10.1038/nrc1209. No abstract available. PMID 14668816
Identifiers
NCT: NCT06836765 · NeijiangPH2